Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

This is an interventional treatment trial for Parkinson's Disease focused on measuring Apomorphine Read More

Inclusion Criteria:

• Female and male subjects aged ≥30;
• Diagnosis of established PD, defined by the Movement Disorders Society PD criteria (Postuma et al., 2015);
• Presence of visual severe hallucinations defined as more than 3 times a week (van Laar et al., 2010);
• Visual hallucinations must have developed after PD diagnosis;
• Visual hallucinations must have been optimally treated with reduction of dopamine agonists if possible, and prescription of clozapine and/or cholinesterase inhibitors if needed;
• Female subjects must complaint with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study, if sexually active;
• Subjects should be able and capable of adhering to the protocol, visit schedules, and medication intake according to the judgement of the investigator.

Exclusion Criteria:

• Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension;
• Patients with a prolonged QT interval corrected for heart rate according to Bazett's formula (QTc) of >450 ms for male and >470 ms for female at screening, or history of a long QT syndrome;
• PD medication change (i.e., dopamine-agonists, amantadine, monoamine oxidase (MAO)-B inhibitors, anticholinergics and cholinesterase inhibitors) in last month prior to initiation (van Laar et al., 2010);
• Active psychosis or a history of significant psychosis;
• Any medical condition that is likely to interfere with an adequate participation in the study including e.g. current diagnosis of unstable epilepsy, clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months.